Provided is a novel probe for a biological specimen for labelling by itself and clearly visualizing one of a specific cell and a specific cell organ in a living body, the probe having excellent spectral characteristics and exhibiting excellent storage stability. The probe for a biological specimen contains, as an active agent, at least one kind of compound represented by a general formula (I). ##STR00001##

A compound for use in the treatment and/or prevention of diseases or disorders wherein an inhibition of protein prenylation is required, which is alternatively chosen among

##STR00001##

wherein R.sub.1 is 2-pyridyl, 3-pyridyl or 4-pyridyl; R.sub.2 represents:

##STR00002##

and wherein R.sub.5 and R.sub.6 represent a hydrogen atom or a (C.sub.1-4)alkyl group; and R.sub.7 represents an arylcarbonyl group, a heteroarylcarbonyl group, a heteroarylacetyl group, a (C.sub.1-C.sub.4)alkoxy-carbonylmethyl group, a

##STR00003##

group. Also disclosed are novel compounds of formulae (I) and (II).

Disclosed are compounds of Formula (IIa), ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3A, R.sup.3B, R.sup.3C, R.sup.3D, R.sup.3E, and R.sup.4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.

A condensed cyclic compound and an organic light-emitting device, the compound being represented by Formula 1:
(A.sub.1).sub.a1-(L.sub.1).sub.b1-(A.sub.2).sub.a2  <Formula 1> wherein, in Formula 1, A.sub.1 is a group represented by Formula 2-1, below, a1 is 1, 2, or 3, and, when a1 is 2 or greater, two or more A.sub.1s are identical to or different from each other, A.sub.2 is a group represented by Formula 2-2, below, a2 is 1, 2, or 3, and, when a2 is 2 or greater, two or more A.sub.2s are identical to or different from each other, ##STR00001##

A condensed cyclic compound and an organic light-emitting device, the compound being represented by Formula 1:
(A.sub.1).sub.a1-(L.sub.1).sub.b1-(A.sub.2).sub.a2  <Formula 1> wherein, in Formula 1, A.sub.1 is a group represented by Formula 2-1, below, a1 is 1, 2, or 3, and, when a1 is 2 or greater, two or more A.sub.1s are identical to or different from each other, A.sub.2 is a group represented by Formula 2-2, below, a2 is 1, 2, or 3, and, when a2 is 2 or greater, two or more A.sub.2s are identical to or different from each other, ##STR00001##

The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy) benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.

Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics.

##STR00001##

A compound with antitumor activities is represented by formula: ##STR00001##
R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently hydrogen, nitro, alkoxy, halogen, unsubstituted or substituted phenyl, or unsubstituted or substituted alkyl or cycloalkyl.

The present invention encompasses compounds of the formula (I): wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. ##STR00001##